



Benjamin F. Cravatt  
*2025 William H. Nichols Medalist*  
Professor, The Scripps Research Institute

Dr. Cravatt is Professor and Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute. His research group is interested in developing chemical proteomic technologies that enable protein and drug discovery on a global scale and applying these methods to characterize biochemical pathways that play important roles in human physiology and disease. Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996. Professor Cravatt joined the faculty at TSRI in 1997. Dr. Cravatt is co-founder of several biotechnology companies, including Activx Biosciences, Abide Therapeutics, Vividion Therapeutics, Boundless Bio, and Belharra Therapeutics. Dr. Cravatt's honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, the ASBMB Merck Award, AACR Award for Achievement in Chemistry in Cancer Research, the Wolf Prize in Chemistry, the Heinrich Wieland Prize, and memberships in the National Academies of Medicine and Sciences.